A Case Controlled Trial Comparing Biologic Therapy vs. Immunomodulators  in Moderate-to-Severe Crohn’s Disease

Syed Osama Talat, Zahoor Ahmed Shah, Jahanzaib, Rakhshanda Naheed, Javeria Sarfraz, Javaria Zafar

A Case Controlled Trial Comparing Biologic Therapy vs. Immunomodulators in Moderate-to-Severe Crohn’s Disease

Authors

Syed Osama Talat, Zahoor Ahmed Shah, Jahanzaib, Rakhshanda Naheed, Javeria Sarfraz, Javaria Zafar

Keywords:

Crohn’s disease; biologic therapy; immunomodulators

Abstract

Moderate-to-severe Crohn’s disease (CD) remains therapeutically challenging, with escalatingcosts and variable outcomes between biologic and immunomodulator (IMM) strategies. Thepresent case-controlled trial enrolled 120 adult patients with active

References

Chebli, J. M. F., et al. (2022). Effectiveness and safety of ustekinumab for moderate to severely active Crohn’s disease: Results from an early access program in Brazil. Journal of Clinical Medicine, 11(21), 6481. https://doi.org/10.3390/jcm11216481

Duan, S., et al. (2025). Comparative efficacy of biologic therapies in Crohn’s disease: A systematic review. Journal of https://doi.org/10.1093/ecco-jcc/jjae143

Downloads

Published

2025-06-30

How to Cite

Syed Osama Talat, Zahoor Ahmed Shah, Jahanzaib, Rakhshanda Naheed, Javeria Sarfraz, Javaria Zafar. (2025). A Case Controlled Trial Comparing Biologic Therapy vs. Immunomodulators in Moderate-to-Severe Crohn’s Disease . International Journal of Pharmacy Research & Technology (IJPRT), 15(2), 143–150. Retrieved from https://www.ijprt.org/index.php/pub/article/view/667